UPB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Upstream Bio Inc (UPB) is not a strong buy for a beginner investor with a long-term focus at this time. The stock lacks immediate positive catalysts, has bearish technical indicators, and faces uncertainty in its clinical trials and financing. While the company shows some financial improvement, it remains unprofitable. Given the lack of strong trading signals and analyst downgrades, holding off on investing in UPB is the most prudent choice.
The technical indicators are bearish. The MACD is above 0 but contracting, suggesting weakening momentum. RSI is neutral at 43.755, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 9.893, with key support at 9.279 and resistance at 10.507.
Upcoming data presentations at the ATS 2026 Conference on May 18, showcasing advancements in biologics and the potential of verekitug in treating inflammatory diseases.
Analyst downgrade by Evercore ISI citing lack of near-term catalysts, ongoing financing overhang, and uncertainty in the COPD trial. Pre-market price is down 0.42%, and the stock has a low probability of significant short-term gains.
In Q4 2025, revenue increased by 8.97% YoY to $668,000, and net income improved by 94.86% YoY but remains negative at -$42.46 million. EPS improved by 85.71% YoY to -0.78, and gross margin remains at 100%. Despite improvements, the company is still unprofitable.
Evercore ISI downgraded the stock to In Line from Outperform with a reduced price target of $15 (down from $40). Analysts remain optimistic about the long-term potential of verekitug but are cautious due to the lack of near-term catalysts and trial uncertainties.
